Search

Nitroarginine

An inhibitor of nitric oxide synthetase which has been shown to prevent glutamate toxicity. … Nitroarginine has been experimentally tested for its ability to prevent ammonia toxicity and ammonia-induced alterations in brain energy and ammonia metabolites. (Neurochem Res 1995:200(4):451-6)

Aranidipine

[A31895] It was developed by Maruko Seiyaku, introduced by Taiho and launched in Japan in 1997.[T88]

Lucatumumab

Paquinimod

The disease affects mainly women of fertile age and progresses in flares with relatively symptom free periods in between. … Paquinimod is developed for the treatment of SLE (Systemic Lupus Erythematosus), which is an autoimmune disease.

Tyramine

There have been reports of hypertensive crisis in patients ingesting tyramine-rich diet in conjunction with monoamine oxidase inhibitors (MAOIs). … An important characteristic of this product is its impediment to cross the blood-brain barrier which restrains its side effects to only nonpsychoactive peripheral sympathomimetic effects.

Rusalatide

TP508 is a non-proteolytic synthetic peptide representing the portion of human thrombin originally identified as the fibroblast high-affinity receptor binding domain.

Xaliproden

Anpocogin

Recombinant nematode anticoagulant protein c2 (rNAPc2) is a specific inhibitor of tissue factor (TF)/factor VIIa complex with novel antithrombotic activity.

AZD0947

As of March 2003, the drug was in phase II trials; however, as of October 2004, it no longer appeared on the company’s development pipeline.

Temanogrel

APD791 is an oral anti-thrombotic drug candidate being evaluated in a Phase 1 clinical trial by Arena.